Geron Corp (GERN): Cash & Equivalents
$77.56M
As of 2025-12-31
$62.64M
As of 2026-06-30
+10.9%
3-year compound annual growth
+50.9%
5-year compound annual growth
+13.8%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $77.56M | -1.8% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $79.02M | +12.8% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $70.02M | +23.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $56.84M | +63.0% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $34.87M | +251.3% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $9.93M | -27.3% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $13.64M | +29.0% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $10.57M | -35.3% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $16.34M | +27.5% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $12.81M | -39.7% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $21.25M | -50.4% | 2018-03-16, Balance as of period end |
| 2014-12-31 | $42.80M | +229.5% | 2017-03-01, Balance as of period end |
| 2013-12-31 | $12.99M | -41.1% | 2016-03-10, Balance as of period end |
| 2012-12-31 | $22.06M | +37.0% | 2015-03-11, Balance as of period end |
| 2011-12-31 | $16.11M | -65.0% | 2014-03-17, Balance as of period end |
| 2010-12-31 | $45.97M | +32.9% | 2013-03-15, Balance as of period end |
| 2009-12-31 | $34.60M | n/a | 2012-03-07, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Geron Corp (GERN) | 2025-12-31 | $77.56M | -1.8% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $61.15M | +46.8% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $164.09M | +359.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $120.72M | -49.3% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $93.68M | -30.9% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $93.03M | +58.9% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $48.30M | -65.4% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $51.09M | +124.1% |
Compare GERN, LAB, EWTX, NUVB side by side · Screen every company in Pharmaceutical Preparations ↗